These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 29348850

  • 1. Novel indazole-based small compounds enhance TRAIL-induced apoptosis by inhibiting the MKK7-TIPRL interaction in hepatocellular carcinoma.
    Yoon JY, Lee JJ, Gu S, Jung ME, Cho HS, Lim JH, Jun SY, Ahn JH, Min JS, Choi MH, Jeon SJ, Lee YJ, Go A, Heo YJ, Jung CR, Choi G, Lee K, Jeon MK, Kim NS.
    Oncotarget; 2017 Dec 22; 8(68):112610-112622. PubMed ID: 29348850
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of MKK7-JNK by the TOR signaling pathway regulator-like protein contributes to resistance of HCC cells to TRAIL-induced apoptosis.
    Song IS, Jun SY, Na HJ, Kim HT, Jung SY, Ha GH, Park YH, Long LZ, Yu DY, Kim JM, Kim JH, Ko JH, Kim CH, Kim NS.
    Gastroenterology; 2012 Nov 22; 143(5):1341-1351. PubMed ID: 22841785
    [Abstract] [Full Text] [Related]

  • 3. Novel TRAIL sensitizer Taraxacum officinale F.H. Wigg enhances TRAIL-induced apoptosis in Huh7 cells.
    Yoon JY, Cho HS, Lee JJ, Lee HJ, Jun SY, Lee JH, Song HH, Choi S, Saloura V, Park CG, Kim CH, Kim NS.
    Mol Carcinog; 2016 Apr 22; 55(4):387-96. PubMed ID: 25647515
    [Abstract] [Full Text] [Related]

  • 4. Tussilago farfara L. augments TRAIL-induced apoptosis through MKK7/JNK activation by inhibition of MKK7‑TIPRL in human hepatocellular carcinoma cells.
    Lee HJ, Cho HS, Jun SY, Lee JJ, Yoon JY, Lee JH, Song HH, Choi SH, Kim SY, Saloura V, Park CG, Kim NS.
    Oncol Rep; 2014 Sep 22; 32(3):1117-23. PubMed ID: 24969837
    [Abstract] [Full Text] [Related]

  • 5. Receptor for activated C kinase 1 promotes hepatocellular carcinoma growth by enhancing mitogen-activated protein kinase kinase 7 activity.
    Guo Y, Wang W, Wang J, Feng J, Wang Q, Jin J, Lv M, Li X, Li Y, Ma Y, Shen B, Zhang J.
    Hepatology; 2013 Jan 22; 57(1):140-51. PubMed ID: 22903704
    [Abstract] [Full Text] [Related]

  • 6. JNK inhibition sensitises hepatocellular carcinoma cells but not normal hepatocytes to the TNF-related apoptosis-inducing ligand.
    Mucha SR, Rizzani A, Gerbes AL, Camaj P, Thasler WE, Bruns CJ, Eichhorst ST, Gallmeier E, Kolligs FT, Göke B, De Toni EN.
    Gut; 2009 May 22; 58(5):688-98. PubMed ID: 19106147
    [Abstract] [Full Text] [Related]

  • 7. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3.
    Chen KF, Chen HL, Liu CY, Tai WT, Ichikawa K, Chen PJ, Cheng AL.
    Biochem Pharmacol; 2012 Mar 15; 83(6):769-77. PubMed ID: 22230479
    [Abstract] [Full Text] [Related]

  • 8. Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma.
    Yamamoto T, Nagano H, Sakon M, Wada H, Eguchi H, Kondo M, Damdinsuren B, Ota H, Nakamura M, Wada H, Marubashi S, Miyamoto A, Dono K, Umeshita K, Nakamori S, Yagita H, Monden M.
    Clin Cancer Res; 2004 Dec 01; 10(23):7884-95. PubMed ID: 15585621
    [Abstract] [Full Text] [Related]

  • 9. Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model.
    El-Shemi AG, Ashshi AM, Na Y, Li Y, Basalamah M, Al-Allaf FA, Oh E, Jung BK, Yun CO.
    J Exp Clin Cancer Res; 2016 May 06; 35():74. PubMed ID: 27154307
    [Abstract] [Full Text] [Related]

  • 10. Galectin-1 Modulates the Survival and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Sensitivity in Human Hepatocellular Carcinoma Cells.
    Li J, Sun RR, Yu ZJ, Liang H, Shen S, Kan Q.
    Cancer Biother Radiopharm; 2015 Oct 06; 30(8):336-41. PubMed ID: 26348206
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice.
    Pei Z, Chu L, Zou W, Zhang Z, Qiu S, Qi R, Gu J, Qian C, Liu X.
    Hepatology; 2004 May 06; 39(5):1371-81. PubMed ID: 15122766
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic protein.
    Wang G, Zhan Y, Wang H, Li W.
    Cancer Chemother Pharmacol; 2012 Mar 06; 69(3):799-805. PubMed ID: 22037880
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase.
    Nakshatri H, Rice SE, Bhat-Nakshatri P.
    Oncogene; 2004 Sep 23; 23(44):7330-44. PubMed ID: 15286701
    [Abstract] [Full Text] [Related]

  • 20. An anthraquinone derivative, emodin sensitizes hepatocellular carcinoma cells to TRAIL induced apoptosis through the induction of death receptors and downregulation of cell survival proteins.
    Subramaniam A, Loo SY, Rajendran P, Manu KA, Perumal E, Li F, Shanmugam MK, Siveen KS, Park JI, Ahn KS, Hui KM, Kumar AP, Sethi G.
    Apoptosis; 2013 Oct 23; 18(10):1175-87. PubMed ID: 23700228
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.